These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15173090)

  • 21. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell cycle dysregulation influences survival in high risk breast cancer patients.
    Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
    Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
    Chung GG; Provost E; Kielhorn EP; Charette LA; Smith BL; Rimm DL
    Clin Cancer Res; 2001 Dec; 7(12):4013-20. PubMed ID: 11751495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.
    Ping B; He X; Xia W; Lee DF; Wei Y; Yu D; Mills G; Shi D; Hung MC
    Int J Oncol; 2006 Nov; 29(5):1103-10. PubMed ID: 17016640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
    Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
    Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
    Camp RL; Dolled-Filhart M; King BL; Rimm DL
    Cancer Res; 2003 Apr; 63(7):1445-8. PubMed ID: 12670887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Studies on recurrent breast cancer--clinicopathological factors and p53, p21Cip1/Waf1 and cyclin D1 protein expression].
    Yamaguchi Y; Hirooka Y; Konishi I; Sato N; Suzuki K; Kaibara N
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):673-7. PubMed ID: 10234299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
    Buchholz TA; Huang EH; Berry D; Pusztai L; Strom EA; McNeese MD; Perkins GH; Schechter NR; Kuerer HM; Buzdar AU; Valero V; Hunt KK; Hortobagyi GN; Sahin AA
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1337-42. PubMed ID: 15275718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA; Mehmi I; Lupu R
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.
    Pérez-Tenorio G; Berglund F; Esguerra Merca A; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Int J Oncol; 2006 May; 28(5):1031-42. PubMed ID: 16596219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer.
    Al-Bazz YO; Underwood JC; Brown BL; Dobson PR
    Eur J Cancer; 2009 Mar; 45(4):694-704. PubMed ID: 19138840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.